Navigation Links
Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
Date:6/16/2011

SAN DIEGO, June 16, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that three elagolix presentations have been accepted for the scientific program at 2011 World Congress on Endometriosis, to be held September 4-7, 2011 in Montpellier, France. This important meeting is sponsored by the World Endometriosis Society and occurs every three years, bringing together clinicians and basic scientists from all over the world to share the latest developments in endometriosis.

"We are very pleased to participate in this prestigious scientific event," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine. "This Congress will highlight the marked increase in both the basic science and clinical research related to endometriosis that has occurred in recent years. Endometriosis profoundly impacts the lives of well over one hundred million women worldwide, and global efforts to improve our understanding of the disorder, its symptoms and treatment, are the highlights of this triennial meeting. We are excited to be an integral part of these initiatives and to provide a detailed update on our potential new therapy."

The acceptance of multiple abstracts and datasets from the development program of elagolix for endometriosis at the 2011 World Congress on Endometriosis is as follows:

Data from the recently completed Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will be presented in a speaking session:

  • "Elagolix, A Novel Oral GnRH Antagonist, Significantly Reduced Endometriosis-Associated Pelvic Pain: Results For The Placebo-Controlled, Double-Blind Period Of A Randomized Phase 2 Study" on Wednesday, September 7, 2011 at 10:30 am

Data from the recently completed Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will also be presented in two distinct poster sessions:

  • "Elagolix, A Novel Oral GnRH Antagonist Improves Quality Of Life In Women With Endometriosis-Associated Pelvic Pain" on Tuesday, September 6, 2011 at 8:00 am
  • "Elagolix, A Novel Oral GnRH Antagonist, Maintained Reduction Of Endometriosis-Associated Pelvic Pain During 24 Weeks Of Treatment" on Wednesday, September 7, 2011 at 8:00 am

In addition, data from the extensive work undertaken to improve our understanding of endometriosis symptoms will be presented at the 11th World Congress on Endometriosis in two separate sessions:

  • "A Qualitative Evaluation of Disease Severity and Bothersomeness of Symptoms In Patients with Endometriosis" on Tuesday, September 6, 2011 at 8:00 am
  • "Perception of Pelvic Pain in Women with Endometriosis: A Focus Group Study" on Wednesday, September 7, 2011 at 11:30 am.  

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and report on Form 10-Q for the quarter ended March 31, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
(Date:3/23/2017)... 23, 2017  Ethicon* today announced the completion ... privately held medical device company that manufactures and ... surgical treatment of Gastroesophageal Reflux Disease (GERD). This ... its portfolio of minimally invasive options for patients ... terms of the transaction have not been disclosed. ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE IMAGEM ... 157, paragraph 4 of Law 6,404/76 and Instruction 358/02 ... informs its shareholders and the market in general that ... subsidiary Centro de Diagnosticos por Imagem Ltda. (" CDI ... interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and ...
Breaking Medicine Technology:
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Los Angeles based healthcare technology company California Healthcom Group (CHG). , The ... and healthcare arena. With headquarters in California, CHG is a growing, internationally recognized ...
(Date:3/23/2017)... York City (PRWEB) , ... March 23, 2017 , ... ... last fall, FaceCradle , the most-funded travel pillow in crowdfunding history, ... speed delivery of its wildly popular travel innovation to Americans. , “We’re excited to ...
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
Breaking Medicine News(10 mins):